Multiple Abstracts Highlighting Vir Biotechnology s Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024 marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
- Company to present important new data from the Phase 2 SOLSTICE chronic hepatitis delta trial - - Conference call scheduled for June 5, 2024, at 6:00 a.m. ET 12:00 p.m. CEST - Vir Biotechnology
Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
20.09.2023 - – Based on a novel human cytomegalovirus vector platform, VIR-1388 was designed with the goal of creating a novel HIV vaccine – – Phase 1 trial supported by the Bill & Melinda Gates Foundation, the National Institute of Allergy and Infectious . Seite 1
– Data from two ongoing clinical trials in people living with chronic hepatitis B infection suggest the combination of an antiviral with an immunomodulator.